8-K: MaxCyte Reports 15% Revenue Increase in Q2 2024, Driven by Strategic Platform Licenses

MaxCyte's second quarter 2024 revenue increased by 15% year-over-year, primarily due to a significant rise in Strategic Platform License (SPL) revenue, despite a decline in core business revenue.

Summary

• MaxCyte announced its financial results for the second quarter and first half of 2024, showing a 15% increase in total revenue for the second quarter, reaching $10.4 million, compared to $9.0 million in the same period last year.
• The company's core business revenue, which excludes SPL program-related revenue, decreased by 9% in the second quarter to $7.6 million.
• However, SPL program-related revenue saw a substantial increase of 279% in the second quarter, reaching $2.9 million.
• For the first half of 2024, total revenue grew by 24% to $21.8 million, while core business revenue declined by 2% to $15.8 million.
• The company's gross profit margin remained strong at 86% for the second quarter and 87% for the first half of the year.
• MaxCyte reported a net loss of $9.4 million for the second quarter and $18.9 million for the first half of 2024, which is an improvement compared to the same periods in 2023.
• The company affirmed its full-year 2024 core business revenue guidance of flat to 5% growth and increased its SPL program-related revenue guidance to approximately $6 million.
• MaxCyte expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth driven by SPL agreements and a healthy cash position, although there are some concerns about the decline in core business revenue.

Positives

• Total revenue increased by 15% in the second quarter of 2024, driven by a 279% increase in SPL program-related revenue.
• The company has secured five new SPL clients year-to-date, expanding its partnerships to 28.
• MaxCyte maintains a strong gross profit margin of 86% in the second quarter of 2024.
• The company's net loss decreased compared to the same period in 2023.
• MaxCyte has a strong cash position with $199.8 million in total cash, cash equivalents, and investments as of June 30, 2024.
• The company increased its SPL program-related revenue guidance for 2024.

Negatives

• Core business revenue declined by 9% in the second quarter of 2024.
• Cell therapy revenue decreased by 6% in the second quarter of 2024.
• Drug discovery revenue decreased by 18% in the second quarter of 2024.
• Operating expenses for the second quarter of 2024 were $20.9 million, slightly higher than the $20.7 million in the same period of 2023.

Risks

• The company's core business revenue is experiencing a decline, which could impact overall growth if not addressed.
• The reliance on SPL program-related revenue means that the company's financial performance is dependent on the success of its partners' programs.
• The company's operating expenses remain high, which could affect profitability.
• The company's future performance is subject to risks and uncertainties, including market conditions and the success of its partners' clinical trials.

Future Outlook

MaxCyte affirms its 2024 core business revenue guidance of flat to 5% growth and increases its SPL program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.

Management Comments

• We are pleased by our second quarter results and our business performance in the first half of 2024 and remain confident we will deliver our full year guidance, said Maher Masoud, President and CEO at MaxCyte.
• We continue to drive commercial execution in cell therapy and believe that we remain the premier cell engineering platform in the industry.

Industry Context

MaxCyte operates in the rapidly growing cell therapy market, providing enabling platform technologies. The company's focus on non-viral engineering approaches aligns with the industry's increasing demand for safer and more efficient cell modification methods. The growth in SPL revenue indicates a strong interest in MaxCyte's technology from cell therapy developers.

Comparison to Industry Standards

• MaxCyte's 86% gross margin in Q2 2024 is very strong, indicating efficient operations and pricing power, which is comparable to other high-growth biotech companies.
• The 279% increase in SPL revenue suggests a strong market demand for their technology, which is a key differentiator compared to companies that rely solely on product sales.
• The company's 28 SPL partnerships indicate a significant level of industry adoption, which is a positive sign compared to companies with fewer strategic collaborations.
• The company's installed base of 723 instruments shows a strong market presence, which is a key metric for platform technology companies.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased SPL guidance.
• Employees may feel more secure due to the company's positive financial performance and growth prospects.
• Customers will benefit from the company's continued investment in its platform technology.
• Suppliers may see increased demand for their products and services due to the company's growth.
• Creditors may view the company as a lower risk due to its strong cash position.

Next Steps

• MaxCyte will host a conference call on August 6, 2024, to discuss the financial results.
• The company will continue to focus on expanding its SPL partnerships and driving commercial execution in cell therapy.

Key Dates

Keywords

Strategic Platform License, SPL, cell therapy, electroporation, revenue, financial results, bioprocessing, cell engineering, EBITDA, gross margin